TScan Therapeutics

TScan is a clinical-stage biopharmaceutical company dedicated to creating life-changing T cell therapies for patients by unleashing the untapped potential of ...

Press Releases - Investor Relations | TScan Therapeutics, Inc.

TScan Therapeutics reports first quarter 2024 financial results and provides corporate update. First patient dosed in Phase 1 clinical trial for the treatment ...

TScan Therapeutics | LinkedIn

TScan Therapeutics | 8169 followers on LinkedIn. Unleash Immunity | TScan is dedicated to creating life-changing T cell therapies for patients by unleashing ...

TScan Therapeutics, Inc. (TCRX) Stock Price, News, Quote & History

Find the latest TScan Therapeutics, Inc. (TCRX) stock quote, history, news and other vital information to help you with your stock trading and investing.

TScan Therapeutics Reports Second Quarter 2024 Financial ...

TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) ...

S-1 - SEC.gov

TScan Therapeutics, Inc. is offering shares of its common stock. This is our initial public offering and no public market currently exists for our shares of ...

TScan Therapeutics, Inc. - AnnualReports.com

TScan Therapeutics, Inc. ... TScan is a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies ( ...

TScan Therapeutics - Bessemer Venture Partners

TScan Therapeutics is harnessing novel T cell systems to extend the promise of immunotherapy.

TScan Therapeutics to Participate in Upcoming Investor Conferences

WALTHAM, Mass., Aug. 29, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on ...

TScan Therapeutics - Forbes

TScan Therapeutics on the 2020 30 Under 30 - Healthcare - Kula and Hachigian are cofounders of Tscan Therapeutics, a cancer immunology company that uses.

Tscan Therapeutics Inc (TCRX) Stock Price & News - Google Finance

Get the latest Tscan Therapeutics Inc (TCRX) real-time quote, historical performance, charts, and other financial information to help you make more informed ...

TScan Therapeutics, Inc. - MassBio

Overview. TScan is dedicated to creating life-changing T cell therapies for patients by unleashing the untapped potential of the human immune system.

Cancer - Tscan Therapeutics - HonorHealth

HonorHealth clinical trials (Cancer - Tscan Therapeutics) - A Phase 1 Basket Study Evaluating the Safety and Feasibility of T-Plex, Autologous Customized T ...

A Basket Study of Customized Autologous TCR-T Cell Therapies in ...

TScan Therapeutics is developing cellular therapies across multiple solid tumors in which autologous participant-derived T cells are engineered to express a ...

TScan Therapeutics - Longwood Fund

Developing novel T cell therapeutics in cancer. TScan Therapeutics was co-founded by Longwood Fund in collaboration with Lasker Award-winner Stephen Elledge of ...

TScan Therapeutics - Great Place To Work

Company Culture at TScan Therapeutics. The employee experience below at TScan Therapeutics, compared to a typical company. Learn More. 96% of employees at TScan ...

TScan Therapeutics Reports Second Quarter 2024 Financial

TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) ...

TScan Therapeutics (@TScan_Tx) / X

Harnessing novel T cell systems to extend the promise of immunotherapy! #TScan #CellTherapy #UnleashImmunity.

TScan Therapeutics Company Profile 2024 - PitchBook

Stock Performance. As of 13-Nov-2024, TScan Therapeutics's stock price is $5.27. Its current market cap is $278M with 53M shares.

TScan Therapeutics | Institution outputs | Nature Index

TScan Therapeutics United States of America (USA). Page navigation. Research. Research. Date range: 1 July 2023 - 30 June 2024. No articles found. TScan ...